Week in Medical Technology

SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts

- Thirteen Renowned Medical Experts Slated to Attend First National Symposium - CORTLAND, N.Y., June 25 /PRNewswire/ -- The first national symposium designed to explore the health impacts of energy drinks will be held next week in New York City when thirteen top experts gather to present rese...

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Oramed was chosen to present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009. Th...

Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons

Radiofrequency ablation is durable after 2 years, compares favorably with endoscopic resection for advanced disease, and reduces the risk for cancer progression SUNNYVALE, Calif., June 3 /PRNewswire/ -- Results from a number of clinical trials were presented during the Digestive Disease Wee...

InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma...

Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008

- Phase IIb study examines efficacy and safety of once-daily TMC278 in treatment-naive adults with HIV-1 - MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the compan...

Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double-...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REB...

Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15)

SEATTLE, May 9 /PRNewswire-USNewswire/ -- The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such as avoiding smoking, maintaining a normal weight and eating a healthy diet. Alan Kristal, Dr.P.H., associate head o...

The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)

Protecting our Future: The COSHAR Foundation's Immunization Project aims to raise awareness of the importance of timely childhood vaccination, and increase vaccine compliance rates CHEVY CHASE, Md., April 23 /PRNewswire/-- The COSHAR Foundation, a nonprofit organization dedi...

'Best Week Ever' for Nothing But Nets

VH1 Produces and Premieres Public Service Announcement With a Little Help From VH1's Hit Series PSA Expands Partnership Between VH1 and Nothing But Nets to Prevent Malaria in Africa NEW YORK, Nov. 5 /PRNewswire/ -- An irritating human-sized ...

NxStage(R) to Recognize Several Key Milestones at American Society of Nephrology's Renal Week 2007

Number of active users of NxStage Home Hemodialysis System exceeds 2007 patients in 2007, having increased 290 percent in past 18 months Seven of the Top Ten Hospitals for Kidney Disease are now NxStage Partners NxStage closes acquisition of Medisystems and announces launch of inno...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...

XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week

WASHINGTON and MENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that it plans to present long-term follow-up data from the CUSTOM I, II and III clinical trials next week at the Cardiovascular Research Foundation's (CRF) twentieth annual Transca...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona...

Breast Cancer Treatment Is Reduced to One Week

Chicago-Area Community Hospital to Offer New Clinical Study to Breast Cancer Patients EVERGREEN PARK, Ill., Jan. 29 /PRNewswire/ -- Little Company of Mary Hospital and Health Care Centers in Evergreen Park, Illinois, near Chicago ( http://www.PursuingPainFreeCancer....

Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week

Variety of new applications spans paleogenomics, paired-end mapping, and gene expression analysis BRANFORD, Conn., Oct. 2 /PRNewswire/ -- 454 Life Sciences, a Roche company, is the subject of three ground-breaking studies published last week in Science, all of which empl...

Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company's products will be presented at Digestive Disease Week(R) 2007, which will be held May 19-24, 2007. Digestive Disease Week...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV...

InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting

Reports 'Picomolar' Potency and Slow Dissociation from HCV Protease WASHINGTON, May 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- InterMune, Inc. (Nasdaq: ITMN) today presented new preclinical data on the company's Hepatitis C virus (HCV) NS3/4A protease inhibitor, ITMN-191, during ...

Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of fin...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

AstraZeneca Focuses Research on Growing Childhood Condition WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ -- AstraZeneca will present several studies today regarding pediatric patients with gastroesophageal reflux disease (GERD) during oral and poster sessions at the annual Digestive Disease Wee...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., , which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announced that Trine Pharmaceuticals, Inc. ("Trin...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced the presentation of results of a successful pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection in patients undergoing colon...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients with Active Disease MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ -- ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target th...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from two ongoing Phase 3 studies (DUET-1 and DUET-2) showed significantly more HIV-1 adult patients with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) ...

PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week

Nuvion Antibody Led to a Sustained Response and Remission in Follow-up to Phase 1 and Phase 1/2 studies and Was Adequately Tolerated in Patients with IV Steroid-Refractory Ulcerative Colitis FREMONT, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- Data presented at the Digestive Disease Week (DDW) ...

Regular Yoga Practice Is Associated With Mindful Eating

...40 percent of the participants practiced yoga more than an hour per week, 46 percent walked for exercise or transportation for at least 90 minutes per week and more than 50 percent engaged in more than 90 minutes of moderate and/or strenuous physical activity per week. The average weight of the stu...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

... Labopharm's trazodone demonstrated significant improvements versus placebo in all three quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night". The incidence of agitation, weight gain and sexual dysfunction in patients ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...pre-filled syringes require no reconstitution or refrigeration. Patients initiate treatment with two injections administered in the deltoid muscle one week apart (Day 1 at 234 mg and Day 8 at 156 mg), followed by injections every month thereafter administered in either the deltoid or gluteal muscle. INVEG...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...ignificant (p<0.0001) increase in mean hemoglobin concentration compared with baseline after receiving velaglucerase alfa at 60 U/kg IV every other week for 12 months. Statistically significant improvements compared with baselines were also observed in platelet and spleen sizes, and nominally significa...

GAA Calls on Secretary Clinton to Speak Out Against Gender-Based Violence During Her Africa Trip

...Secretary of State Hillary Clinton's departure for a seven-nation tour of Africa: "We applaud Secretary Clinton's decision to visit Africa next week and her decision to focus attention during her visit on preventing conflict and violence, including gender-based violence, on the African continent. ...

British Woman Celebrates a Year of Living Cancer-Free

...daughter into TaNK cells, which can kill even NK-resistant tumors. Within a week of the injection, the TaNK cells had survived and multiplied. Within a mont...dday and go to work then, but I haven't been. I've been working five days a week from 9 to 5. I've been feeling fine," Ms. Scott said. Her good healt...

New Powder Speeds Healing of Difficult Foot Wounds

...atric Medicine. The study focused on atypical wounds with irregular shapes and causes. The wounds were treated with the powder dressing once a week for four to eight weeks. The study ultimately showed that the powder dressing provided a painless, efficient, and protective treatment that assisted ...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...patient's own immune cells (dendritic cells) and 500 micrograms of granulocyte-colony stimulating factor (GM-CSF), an immune stimulator, three times a week and then monthly for five months for a total of up to eight injections. The patient's dendritic cells were obtained from their peripheral blood and mi...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... presented at the NCDEU meeting focused on the MITT population using both the LOCF and MMRM analyses for the co-primary endpoints. The CGI-I at week six demonstrated improvement relative to placebo using the MITT LOCF, MITT MMRM. The mean CGI-I scores were statistically significant relative to plac...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

...mages of the subjects before and after three weeks of treatment, confirmed the effects were significant and noticeable. Dryness reversed in one week (after switching from regular body wash) Softer, smoother skin all over More even skin tone The new NutriumMoisture techn...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...d placebo response rates were considerably higher than seen in any other previous study of RA biologic failure patients and rose unaccountably between week 6 (at which point the reported response rates between R788 and placebo were significantly different) and month 3 (when such reported response rates we...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...ients with type 2 diabetes taking stable doses of metformin alone or in combination with a sulfonylurea. Exenatide once weekly was administered once a week in a fixed dose while Lantus was administered daily in a variable dose determined by patient blood sugar levels. "Exenatide once weekly outpe...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

...ies/mL measured at two consecutive visits prior to week 48 (i.e. suppression at weeks 24 and 36) and witho...t subsequent rebound or change of therapy prior to week 48. In the primary analysis of the primary endpoin...o 0.98, p=0.63] at two consecutive visits prior to week 48 and without subsequent rebound or change of ant...